Treatment-refractory actinic keratoses successfully treated using simultaneous combination topical 5-fluorouracil cream and imiquimod cream: A case-control study

Dermatologic Surgery

Volumn 38, Issue 9, 2012, Pages 1469-1476

  Ondo, Andrew L ^a,b   Padilla, R Steven ^a   Miedler, John D ^c   Cockerell, Clay J ^c   Kerner, James D ^b   Steiner, Robert L ^d   Mings, Steven M ^e   Shanler, Stuart D ^f  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^b NEW MEXICO STATE UNIVERSITY   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d NEW MEXICO STATE UNIVERSITY   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

^f PRIVATE PRACTICE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; IMIQUIMOD;

ACTINIC KERATOSIS; ADULT; AGED; ARTICLE; CASE REPORT; CONTROLLED STUDY; CRYOTHERAPY; EPIDERMIS; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; MALE; MONOTHERAPY; PRIORITY JOURNAL; SEX DIFFERENCE; SKIN BIOPSY; SKIN DEFECT; SKIN PAIN; SKINFOLD THICKNESS; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; AMINOQUINOLINES; ANALYSIS OF VARIANCE; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; CRYOSURGERY; DRUG THERAPY, COMBINATION; FEMALE; FLUOROURACIL; HUMANS; KERATOSIS, ACTINIC; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT FAILURE;

EID: 84866391121     PISSN: 10760512     EISSN: 15244725     Source Type: Journal    
DOI: 10.1111/j.1524-4725.2012.02480.x     Document Type: Article

References (23)

1. Marks R, Rennie G, Selwood TS. Malignant transformation of solar keratoses to squamous cell carcinoma. Lancet 1988;1 (8589):795-7. (Pubitemid 18094914)
2. Fuchs A, Marmur E. The kinetics of skin cancer: progression of actinic keratosis to squamous cell carcinoma. Dermatol Surg 2007;33:1099-101. (Pubitemid 47339694)
3. Dinehart SM. The treatment of actinic keratoses. J Am Acad Dermatol 2000;42:S258 (Pubitemid 30481728)
4. Quaedvlieg PJ, Tirsi E, Thissen MR, Krekels GA. Actinic keratosis: how to differentiate the good ones from the bad ones? Eur J Dermatol 2006;16:3359. (Pubitemid 44328971)
5. Fu W, Cockerell CJ. The actinic (solar) keratosis: a 21st-century perspective. Arch Dermatol 2003;139:6670. (Pubitemid 36091577)
6. Marks VJ. Actinic keratosis. A premalignant skin lesion. Otolaryngol Clin North Am 1993;26:2335. (Pubitemid 23069903)
7. Dodson JM, DeSpain J, Hewett JE, Clark DP. Malignant potential of actinic keratoses and the controversy over treatment. A patient-oriented perspective. Arch Dermatol 1991;127: 1029-31.
8. Suchniak JM, Baer S, Goldberg LH. High rate of malignant transformation in hyperkeratotic actinic keratoses. J Am Acad Dermatol 1997;37:3924. (Pubitemid 27430634)
9. Tomas D, Kruslin B, Cupic H, Stanimirovic A, et al. Correlation between bcl-2 and bax in atrophic and hypertrophic type of actinic keratosis. J Eur Acad Dermatol Venereol 2006;20:517.
10. Berhane T, Halliday GM, Cooke B, Barnetson RS. Inflammation is associated with progression of actinic keratoses to squamous cell carcinomas in humans. Br J Dermatol 2002;146:810-5. (Pubitemid 34539190)
11. Pehoushek J, Smith KJ. Imiquimod and 5% fluorouracil therapy for anal and perianal squamous cell carcinoma in situ in an HIV- 1-positive man. Arch Dermatol 2001;137:146. (Pubitemid 32096351)
12. Smith KJ, Germain M, Skelton H. Squamous cell carcinoma in situ (Bowen's disease) in renal transplant patients treated with 5% imiquimod and 5% 5-fluorouracil therapy. Dermatol Surg 2001;27:5614. (Pubitemid 32552911)
13. Ondo AL, Mings SM, Pestak RM, Shanler SD. Topical combination therapy for cutaneous squamous cell carcinoma in situ with 5-fluorouracil cream and imiquimod cream in patients who have failed topical monotherapy. J Am Acad Dermatol 2006;55:10924.
14. Sauder DN. Immunomodulatory and pharmacologic properties of imiquimod. J Am Acad Dermatol 2000;43(Suppl):S6-11. (Pubitemid 30447906)
15. Imbertson LM, Beaurline JM, Couture AM, Gibson SJ, et al. Cytokine induction in hairless mouse and rat skin after topical application of the immune response modifiers imiquimod and S-28463. J Invest Dermatol 1998;110:7349. (Pubitemid 28194019)
16. Geisse J, Caro I, Lindholm J, Golitz L, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol 2004;50:72233. (Pubitemid 38580549)
17. Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003;3:3308. (Pubitemid 37328853)
18. Makower D, Wadler S. Interferons as biomodulators of fluoropyrimidines in the treatment of colorectal cancer. Semin Oncol 1999;26:66371. (Pubitemid 30013273)
19. Teicher BA, Ara G, Buxton D, Leonard J, et al. Optimal scheduling of interleukin-12 and chemotherapy in the murine MB-49 bladder carcinoma and B16 melanoma. Clin Cancer Res 1997;3:1661-7. (Pubitemid 27431577)
20. Roosterman D, George T, Schneider SW, Bunnett NW, et al. Neuronal control of skin function: the skin as a neuroimmunoendocrine organ. Physiol Rev 2006;86:130979. (Pubitemid 44523706)
21. Slominski A, Wortsman J. Neuroendocrinology of the skin. Endocr Rev 2000;21:45787.
22. Slominski A, Wortsman J, Luger T, Paus R, et al. Corticotropin releasing hormone and proopiomelanocortin involvement in the cutaneous response to stress. Physiol Rev 2000;80:979-1020. (Pubitemid 30452009)
23. Fukamizu H, Inoue K, Matsumoto K, Okayama H, et al. Metastatic squamous-cell carcinomas derived from solar keratosis. J Dermatol Surg Oncol 1985;11:518-22.